ID

15274

Description

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00237211

Link

https://clinicaltrials.gov/show/NCT00237211

Keywords

  1. 5/24/16 5/24/16 -
Uploaded on

May 24, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211

Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with histologically documented breast cancer.
Description

breast cancer

Data type

boolean

Alias
UMLS CUI [1]
C0678222
patients with hormone receptor (er and/or pgr) status of positive or unknown
Description

hormone receptor status

Data type

boolean

Alias
UMLS CUI [1]
C0019929
patients who have been amenorrheic for the preceding 12 months or more.
Description

amenorrheic

Data type

boolean

Alias
UMLS CUI [1]
C0002453
patients who are 20 years or older and younger than 75 years.
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. the endocrine therapy, however, should not exceed one regimen.
Description

therapeutic procedures

Data type

boolean

Alias
UMLS CUI [1]
C0087111
patients with progressing lesions.
Description

progressing lesions

Data type

boolean

Alias
UMLS CUI [1,1]
C0221198
UMLS CUI [1,2]
C0205329
patients with sufficient organ function to evaluate the safety
Description

sufficient organ function

Data type

boolean

Alias
UMLS CUI [1,1]
C1254358
UMLS CUI [1,2]
C0205410
patients whose performance status (ps) is classified in 0~2.
Description

performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
patients who have no residual effects from previous treatments
Description

ID.9

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).
Description

malignant disease

Data type

boolean

Alias
UMLS CUI [1]
C0006826
patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)
Description

hypercalcemia and uncontrollable cardiac disease

Data type

boolean

Alias
UMLS CUI [1]
C0020437
UMLS CUI [2]
C0018799
patients who have previously received aromatase inhibitor.
Description

aromatase inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C0593802
patients who have lymphangitis-type lung metastasis or symptomatic brain metastasis.
Description

lymphangitis-type lung metastasis or symptomatic brain metastasis

Data type

boolean

Alias
UMLS CUI [1]
C0153676
UMLS CUI [2]
C0220650
other protocol-defined inclusion / exclusion criteria may apply.
Description

other inclusion criteria

Data type

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0205394

Similar models

Eligibility Postmenopausal Women With Advanced Breast Cancer NCT00237211

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
breast cancer
Item
patients with histologically documented breast cancer.
boolean
C0678222 (UMLS CUI [1])
hormone receptor status
Item
patients with hormone receptor (er and/or pgr) status of positive or unknown
boolean
C0019929 (UMLS CUI [1])
amenorrheic
Item
patients who have been amenorrheic for the preceding 12 months or more.
boolean
C0002453 (UMLS CUI [1])
age
Item
patients who are 20 years or older and younger than 75 years.
boolean
C0001779 (UMLS CUI [1])
therapeutic procedures
Item
patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. the endocrine therapy, however, should not exceed one regimen.
boolean
C0087111 (UMLS CUI [1])
progressing lesions
Item
patients with progressing lesions.
boolean
C0221198 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
sufficient organ function
Item
patients with sufficient organ function to evaluate the safety
boolean
C1254358 (UMLS CUI [1,1])
C0205410 (UMLS CUI [1,2])
performance status
Item
patients whose performance status (ps) is classified in 0~2.
boolean
C1520224 (UMLS CUI [1])
ID.9
Item
patients who have no residual effects from previous treatments
boolean
Item Group
C0680251 (UMLS CUI)
malignant disease
Item
patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).
boolean
C0006826 (UMLS CUI [1])
hypercalcemia and uncontrollable cardiac disease
Item
patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)
boolean
C0020437 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
aromatase inhibitor
Item
patients who have previously received aromatase inhibitor.
boolean
C0593802 (UMLS CUI [1])
lymphangitis-type lung metastasis or symptomatic brain metastasis
Item
patients who have lymphangitis-type lung metastasis or symptomatic brain metastasis.
boolean
C0153676 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
other inclusion criteria
Item
other protocol-defined inclusion / exclusion criteria may apply.
boolean
C1512693 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial